Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells

NCT00078520 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Leukemia, B-Cell, Chronic

Interventions

BIOLOGICAL: Dose Level 1
BIOLOGICAL: Dose Level 2
BIOLOGICAL: Dose Level 2- Fixed Dose

Sponsor

Baylor College of Medicine

Collaborators

[object Object]
[object Object]